{"id":"fibrogammin","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["Factor XIII"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Fibrogammin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:54:31.706003+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:54:50.378270+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:54:37.660089+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fibrogammin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:54:39.113802+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Fibrogammin, marketed by Christian Haslinger, is a therapeutic agent with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status, providing a competitive edge over pre-market competitors. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.","ecosystem":[],"_scrapedAt":"2026-03-27T23:30:26.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:54:50.378361+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03741023","phase":"NA","title":"Disorders of the Acute Phase Response Following Trauma and Invasive Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2019-12-12","conditions":"Acute Phase Response","enrollment":320},{"nctId":"NCT06070350","phase":"PHASE3","title":"Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children","status":"RECRUITING","sponsor":"Philip Spinella","startDate":"2024-11-01","conditions":"Hemorrhagic Shock, Trauma Injury","enrollment":1000},{"nctId":"NCT05631847","phase":"NA","title":"Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke","status":"COMPLETED","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2023-04-17","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis","enrollment":345},{"nctId":"NCT03424460","phase":"NA","title":"Venous Thromboembolism in Myotonic Dystrophy Type 1","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-06-11","conditions":"Myotonic Dystrophy 1","enrollment":130},{"nctId":"NCT07098676","phase":"","title":"Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Ai Peng","startDate":"2024-11-20","conditions":"Healthy Individuals (Controls), Vascular Surgery Patients With Acute Thrombosis, Dialysis Patients","enrollment":900},{"nctId":"NCT05899465","phase":"PHASE3","title":"Perioperative Treatment With Tranexamic Acid in Melanoma","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2023-08-25","conditions":"Melanoma","enrollment":1204},{"nctId":"NCT06481995","phase":"PHASE4","title":"SWIFT - SWIss Factor XIII Trial in PPH","status":"RECRUITING","sponsor":"Christian Haslinger","startDate":"2024-07-09","conditions":"Postpartum Hemorrhage, Coagulation Disorder, Coagulation Factor Deficiency","enrollment":988},{"nctId":"NCT04814433","phase":"PHASE4","title":"Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2021-03-24","conditions":"Opioid Pain Medication","enrollment":46},{"nctId":"NCT06379126","phase":"","title":"The Diagnostic and Prognostic Value of TAT, PIC, tPAI·C and TM in Sepsis-induced Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2024-04-20","conditions":"Sepsis-induced Coagulopathy","enrollment":210},{"nctId":"NCT05540834","phase":"PHASE2","title":"Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure","status":"RECRUITING","sponsor":"South West Sydney Local Health District","startDate":"2022-05-18","conditions":"Acute Respiratory Failure, Hypercoagulability, Fibrinolysis Shutdown","enrollment":70},{"nctId":"NCT05024253","phase":"PHASE3","title":"Perioperative Use of Tranexamic (TXA) in Bone Tumor Surgery Will Change in Blood Loss and Transfusion Requirements.","status":"COMPLETED","sponsor":"Children's Cancer Hospital Egypt 57357","startDate":"2021-08-02","conditions":"Ewing Sarcoma of Bone, Osteosarcoma","enrollment":48},{"nctId":"NCT05966012","phase":"","title":"Tranexamic Acid Dose and Confusion After Cardiac Surgery","status":"UNKNOWN","sponsor":"Papworth Hospital NHS Foundation Trust","startDate":"2023-02-01","conditions":"Cardiovascular Surgery","enrollment":5000},{"nctId":"NCT02187120","phase":"PHASE3","title":"Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)","status":"COMPLETED","sponsor":"Monash University","startDate":"2014-07-28","conditions":"Wounds and Injuries, Acute Coagulopathy","enrollment":1310},{"nctId":"NCT04372940","phase":"PHASE4","title":"Tranexamic Acid in Gender Mastectomy","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2023-01","conditions":"Surgery","enrollment":""},{"nctId":"NCT02257580","phase":"PHASE4","title":"The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2015-04-01","conditions":"E-Aminocaproic Acid, Bilateral Varus Rotational Osteotomy","enrollment":28},{"nctId":"NCT04373603","phase":"PHASE4","title":"Use of Tranexamic Acid in Facial Fillers","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2022-07","conditions":"Injection Site Bruising","enrollment":""},{"nctId":"NCT02797119","phase":"PHASE4","title":"Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2016-03-15","conditions":"Pregnancy Complications, Hemorrhage","enrollment":225},{"nctId":"NCT03317795","phase":"PHASE4","title":"Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids","status":"COMPLETED","sponsor":"Shannon K. Laughlin-Tommaso","startDate":"2017-11-14","conditions":"Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids","enrollment":18},{"nctId":"NCT01585259","phase":"PHASE1, PHASE2","title":"Anfibatide Phase Ib-IIa Clinical Trial","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2012-07","conditions":"Non-ST Segment Elevation Myocardial Infarction","enrollment":90},{"nctId":"NCT04582188","phase":"","title":"The Early Coagulopathy for the Prognosis in Sepsis","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2020-11-05","conditions":"Sepsis, Coagulopathy, Outcome, Fatal","enrollment":200},{"nctId":"NCT04404790","phase":"PHASE1","title":"Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers","status":"SUSPENDED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-09","conditions":"Antiplatelet Drug","enrollment":50},{"nctId":"NCT03386656","phase":"PHASE3","title":"Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2017-11-28","conditions":"Osteoarthritis, Knee","enrollment":150},{"nctId":"NCT04218890","phase":"","title":"TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-04-01","conditions":"Lupus Nephritis","enrollment":100},{"nctId":"NCT03469206","phase":"NA","title":"Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2018-02-21","conditions":"Ischemic Stroke, Large Vessel Occlusion, Thrombectomy","enrollment":656},{"nctId":"NCT04021173","phase":"PHASE2","title":"A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2019-07","conditions":"Acquired Thrombotic Thrombocytopenic Purpura","enrollment":74},{"nctId":"NCT01089140","phase":"PHASE2","title":"Non-Idiopathic Scoliosis Treated With Tranexamic Acid","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-11","conditions":"Non-idiopathic Scoliosis","enrollment":2},{"nctId":"NCT00348439","phase":"PHASE2","title":"Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment","status":"TERMINATED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-04","conditions":"Vitreoretinal Traction Syndrome","enrollment":29},{"nctId":"NCT00347646","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)","status":"TERMINATED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-09","conditions":"Vitreoretinal Traction Syndrome","enrollment":4},{"nctId":"NCT01990768","phase":"PHASE2","title":"Prehospital Tranexamic Acid Use for Traumatic Brain Injury","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-05","conditions":"Traumatic Brain Injury","enrollment":967},{"nctId":"NCT00640289","phase":"NA","title":"Clinical Trial of Factor XIII (FXIII) Concentrate","status":"COMPLETED","sponsor":"Children's Hospital of Orange County","startDate":"2000-01","conditions":"Hemophilia, Factor XIII Deficiency","enrollment":72},{"nctId":"NCT03188913","phase":"","title":"Factor XIII in Major Burns Coagulation","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2017-06-19","conditions":"Burns, Coagulation Disorder, Factor XIII Deficiency","enrollment":20},{"nctId":"NCT01694537","phase":"PHASE2","title":"The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2012-07","conditions":"Healthy","enrollment":21},{"nctId":"NCT03078257","phase":"PHASE1","title":"Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-01-01","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT01222117","phase":"PHASE2","title":"A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2010-12","conditions":"Acute Peripheral Arterial Occlusion","enrollment":174},{"nctId":"NCT00418483","phase":"PHASE1","title":"A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2007-03","conditions":"Arterial Occlusive Diseases","enrollment":83},{"nctId":"NCT02653261","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology","status":"COMPLETED","sponsor":"University Tunis El Manar","startDate":"2016-01","conditions":"Hemorrhage","enrollment":131},{"nctId":"NCT02551042","phase":"PHASE2","title":"CSL Behring Sclero XIII","status":"UNKNOWN","sponsor":"University College, London","startDate":"2015-09","conditions":"Systemic Sclerosis","enrollment":26},{"nctId":"NCT01545635","phase":"PHASE3","title":"RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma","status":"TERMINATED","sponsor":"Medical University Innsbruck","startDate":"2012-03","conditions":"Major Trauma","enrollment":100},{"nctId":"NCT01014975","phase":"PHASE1, PHASE2","title":"A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2009-11","conditions":"Acute Ischemic Stroke","enrollment":40},{"nctId":"NCT01828138","phase":"NA","title":"Hypertension and Urine Protease Activity in Preeclampsia","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2013-05","conditions":"Preeclampsia, Hypertension, Proteinuria","enrollment":35},{"nctId":"NCT01821053","phase":"","title":"Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2013-06","conditions":"Preeclampsia, Type 1 Diabetes","enrollment":85},{"nctId":"NCT02495012","phase":"PHASE2","title":"Anfibatide Treatment in STEMI Patients","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2015-08","conditions":"ST Segment Elevation Myocardial Infarction","enrollment":240},{"nctId":"NCT00945906","phase":"PHASE3","title":"An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2009-09","conditions":"Factor XIII Deficiency","enrollment":61},{"nctId":"NCT01535222","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-11","conditions":"Coronary Artery Bypass Graft, Cardiopulmonary Bypass","enrollment":32},{"nctId":"NCT00885742","phase":"PHASE3","title":"A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2009-08","conditions":"Factor XIII Deficiency","enrollment":41},{"nctId":"NCT01588132","phase":"PHASE1","title":"Anfibatide Phase 1 Clinical Trial in Healthy Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2010-09","conditions":"Coronary Heart Disease, Coagulation Disorder","enrollment":94},{"nctId":"NCT00883090","phase":"PHASE2","title":"A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2009-05","conditions":"Factor XIII Deficiency","enrollment":15},{"nctId":"NCT01478516","phase":"NA","title":"Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2011-11","conditions":"Macular Edema","enrollment":40},{"nctId":"NCT00354900","phase":"PHASE1","title":"Phase I Study of Aprotinin in Advanced Breast Cancer","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2006-07","conditions":"Metastatic Breast Cancer","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"DRUG INEFFECTIVE"},{"count":11,"reaction":"NO ADVERSE EVENT"},{"count":8,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":7,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":6,"reaction":"ABORTION SPONTANEOUS"},{"count":6,"reaction":"DEVICE ISSUE"},{"count":6,"reaction":"FACTOR XIII INHIBITION"},{"count":6,"reaction":"HAEMORRHAGE"},{"count":6,"reaction":"OFF LABEL USE"},{"count":5,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":39,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Fibrogammin","genericName":"Fibrogammin","companyName":"Christian Haslinger","companyId":"christian-haslinger","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:54:50.378361+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}